AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Treatment-naïve patients with newly diagnosed nodal T-cell lymphoma with T-follicular helper (TFH) phenotype as determined by the following 2016 WHO diagnostic criteria:
✓. 20 to 85 years of age at diagnosis
✓. ECOG performance status 0-2
✓. Cardiac function suitable for chemotherapy: LVEF ≥45% on echocardiography or MUGA
✓. Appropriate renal function: Serum Cr ≤2.0mg/dL or eGFR ≥ 30mL/min according to the Cockroft-Gault formula
✓. Appropriate hepatic function: ALT ≤2.5x upper limit of normal (ULN) (or ≤5x ULN in the presence of liver involvement), total bilirubin ≤2x ULN (or ≤3x ULN in the presence of liver involvement)
✓. Appropriate hematologic findings: absolute neutrophil count (ANC) ≥1,500/μL, platelets ≥100,000/μL (or ANC ≥500/μL and platelets ≥50,000/ μL in the presence of bone marrow involvement)
✓. Written informed consent to participate in the study
Exclusion criteria
✕. Other subtypes of non-Hodgkin's lymphoma
✕. History of chemotherapy for Hodgkin's or other non-Hodgkin's lymphoma in the last 5 years
✕. History of active cancer diagnosed within the last 3 years (with the exception of completely resected non-melanoma skin cancer, papillary thyroid cancer, carcinoma in situ of cervical cancer or breast cancer, and localized prostate cancer)
✕. Uncontrolled hepatitis B (with the exception of asymptomatic HBsAg-positive or anti-HBcAb-positive cases receiving antiviral prophylaxis such as entecavir or tenofovir)
✕. History of chronic hepatitis C (with the exception of HCV IgG positive with a negative HCV-RNA quantification)
✕. History of human immunodeficiency virus (HIV) infection
✕. Congestive heart failure (NYHA class ≥3)
✕. Acute coronary syndrome (new-onset unstable angina or myocardial infarction) or ventricular tachycardia within 6 months prior to study entry